Start-up NanoSomix Looks to Mine Neuronal Exosomes for Alzheimer's Protein Markers | GenomeWeb

NEW YORK (GenomeWeb) – Biotech start-up NanoSomix said this week that it plans to launch its exosome-based Alzheimer's assay this fall, targeting the product at academic and pharmaceutical researchers investigating the disease.

The assay isolates neuronal exosomes in patient blood and then measures their levels of the Alzheimer's biomarkers amyloid-β42 and phosphorylated tau protein. According to President and CEO John Osth, this approach lets the company measure patient biomarkers without needing to perform lumbar punctures to collect cerebrospinal fluid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.